Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Muc4/sialomucin complex, an intramembrane modulator of ErbB2/HER2/Neu, potentiates primary tumor growth and suppresses apoptosis in a xenotransplanted tumor

Abstract

Overexpression of the membrane mucin MUC4/Sialomucin complex (SMC) has been observed during malignant progression of mammary tumors in both humans and rats, suggesting that deregulation of MUC4/SMC expression might facilitate development of these malignancies. As previously reported, overexpression of SMC results in suppression of both cell adhesion and immune killing of tumor cells. SMC also acts as a ligand for ErbB2/Neu, modulating phosphorylation of the receptor tyrosine kinase in the presence and absence of heregulin. The present studies investigated the effect of Muc4/SMC up-regulation on primary tumor growth using a tetracycline-inducible SMC expression system in a xenotransplanted tumor model. SMC up-regulation provoked rapid growth of transfected A375 melanoma in nude mice. Up-regulation of SMC, however, did not significantly increase proliferation of A375 cells in vitro. Instead, a strong suppression of apoptosis was observed in situ in SMC-overexpressing tumors. These data suggest that Muc4/SMC expression promotes tumor growth in vivo at least in part via suppression of tumor cell apoptosis. Importantly, reduction of apoptosis was also observed in vitro, indicating that anti-apoptotic effect of SMC is independent of tumor-host interactions. These findings strongly suggest that SMC up-regulation alters intracellular signaling to favor cell survival, providing for the first time evidence for the regulation of programmed cell death by a gene of the MUC family.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7

Similar content being viewed by others

References

  • Arteaga CL, Dugger TC and Hurd SD. . 1996 Breast Cancer Res. Treatment 38: 49–56.

  • Assoian RK. . 1997 J. Cell Biol. 136: 1–4.

  • Bhavanandan VP. . 1991 Glycobiology 1: 493–503.

  • Boudreau N and Bissell MJ. . 1998 Curr. Opin. Cell Biol. 10: 640–646.

  • Boudreau N, Sympson CJ, Werb Z and Bissell MJ. . 1995 Science 267: 891–893.

  • Carraway CAC, Carvajal ME and Carraway KL. . 1999a J. Biol. Chem. 274: 25659–25667.

  • Carraway KL, Fregien N, Carraway CAC and Carraway III KL. . 1992 J. Cell Sci. 103: 299–307.

  • Carraway KL, Price-Schiavi SA, Komatsu M, Idris N, Perez A, Li P, Jepson S, Zhu X, Carvajal ME and Carraway CAC. . 2000 Front. Biosci. 5: 95–107.

  • Carraway III KL, Rossi EA, Komatsu M, Price-Schiavi SA, Huang D, Guy PM, Carvajal ME, Fregien NL, Carraway CAC and Carraway KL. . 1999b J. Biol. Chem. 274: 5263–5266.

  • Dhawan J, Rando TA, Elson SL, Bujard H and Blau HM. . 1995 Somat. Cell. Mol. Gen. 21: 233–240.

  • Duriez PJ and Shah GM. . 1997 Biochem. Cell Biol. 75: 337–349.

  • Idris N and Carraway KL. . 2000 J. Cell Physiol. 185: 310–316.

  • Hanahan D, Christofori G, Naik P and Arbeit J. . 1996 Eur. J. Cancer 32: 2386–2393.

  • Huggins JW, Trenbeath TP, Sherblom AP, Howard SC and Carraway KL. . 1980 Cancer Res. 40: 1873–1878.

  • Idris N and Carraway KL. . 2000 J. Cell Physiol. 185: 310–316.

  • Komatsu M, Carraway CAC, Fregien NL and Carraway KL. . 1997 J. Biol. Chem. 272: 33245–33254.

  • Komatsu M, Yee L and Carraway KL. . 1999 Cancer Res. 59: 2229–2236.

  • Komatsu M, Tatum L, Altman N, Carraway CAC and Carraway KL. . 2000 Int. J. Cancer 87: 480–486.

  • Lochter A, Galosy S, Muschler J, Freedman N, Werb Z and Bissell MJ. . 1997 J. Cell Biol. 139: 1861–1872.

  • Meredith JE, Fazeli B and Schwartz MA. . 1993 Mol. Biol. Cell. 4: 953–961.

  • Meredith JE and Schwartz MA. . 1997 Trends Cell Biol. 7: 146–150.

  • Moniaux N, Nollet S, Porchet N, Degand P, Laine A and Aubert JP. . 1999 Biochem. J. 338: 325–333.

  • Pandey P, Kharbanda S and Kufe D. . 1995 Cancer Res. 55: 4000–4003.

  • Passman RS and Fishman GI. . 1994 J. Clin. Invest. 94: 2421–2425.

  • Price-Schiavi SA, Carraway CAC, Fregien N and Carraway KL. . 1998 J. Biol. Chem. 273: 35228–35237.

  • Price-Schiavi SA, Zhu X, Aquinin R and Carraway KL. . 2000 J. Biol. Chem. 275: 17800–17807.

  • Rossi EA, McNeer R, Price-Schiavi SA, Komatsu M, Van den Brande JMH, Thompson JF, Carraway CAC, Fregien NL and Carraway KL. . 1996 J. Biol. Chem. 271: 33476–33485.

  • Sherblom AP, Buck RL and Carraway KL. . 1980 J. Biol. Chem. 255: 783–790.

  • Sheng Z, Hull SR and Carraway KL. . 1990 J. Biol. Chem. 265: 8505–8510.

  • Sheng Z, Wu K, Carraway KL and Fregien N. . 1992 J. Biol. Chem. 267: 16341–16346.

  • Sternlicht MD, Lochter A, Sympson CJ, Huey B, Rougier JP, Gray JW, Pinkel D, Bissell MJ and Werb Z. . 1999 Cell 98: 137–146.

  • Strous GJ and Dekker J. . 1992 Crit. Rev. Biochem. Mol. Biol. 27: 57–92.

  • Sympson CJ, Talhouk RS, Alexander CM, Chin JR, Clift SM, Bissell MJ and Werb Z. . 1994 J. Cell Biol. 125: 681–693.

  • Talhouk RS, Bissell MJ and Werb Z. . 1992 J. Cell Biol. 118: 1271–1282.

  • Tlsty TD. . 1998 Curr. Opin. Cell Biol. 10: 647–653.

  • van de Wiel-van Kemenade E, Ligtenberg MJ, de Boer AJ, Buijs F, Vos HL, Melief CJ, Hilkens J and Figdor CG. . 1993 J. Immunol. 151: 767–776.

  • Wesseling J, van der Valk SW, Vos HL, Sonnenberg A and Hilkens J. . 1995 J. Cell Biol. 129: 255–265.

  • Wu K, Fregien N and Carraway KL. . 1994a J. Biol. Chem. 269: 11950–11955.

  • Wu K, Salas PJI, Yee L, Fregien N and Carraway KL. . 1994b Oncogene 9: 3139–3147.

  • Zrihan-Licht S, Baruch A, Elroy-Stein O, Keydar I and Wreschner DH. . 1994 FEBS Lett. 356: 130–136.

Download references

Acknowledgements

FACScan analyses were done at the Sylvester Cancer Center Flow Cytometry Facility of the University of Miami. This research was supported in part by Grants CA74072 and CA52498 from the National Institutes of Health and by the Sylvester Comprehensive Cancer Center of the University of Miami.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Komatsu, M., Jepson, S., Arango, M. et al. Muc4/sialomucin complex, an intramembrane modulator of ErbB2/HER2/Neu, potentiates primary tumor growth and suppresses apoptosis in a xenotransplanted tumor. Oncogene 20, 461–470 (2001). https://doi.org/10.1038/sj.onc.1204106

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1204106

Keywords

This article is cited by

Search

Quick links